Predict your next investment

xABT company logo
HEALTHCARE | Biotechnology

See what CB Insights has to offer

Founded Year



Series B | Alive

Total Raised


Last Raised

$7.08M | 1 yr ago

About xABT

xABT is a molecular diagnostic enterprise specializing in the development of detection solutions for pathogenic microbes.

xABT Headquarter Location

1F, Block B, Zhengdan International 33 Science Park Road, Changping District

Beijing, Beijing, 102206,


+86 010-80727800

Latest xABT News

XABT Donates 2019-nCoV Nucleic Acid Detection Kits to Vientiane, Laos

Aug 27, 2021

PRNewsWire India BEIJING, Aug. 25, 2021 /PRNewswire/ -- Atsaphangthong Siphandone, Mayor of Vientiane, the capital of Laos, recently issued an honorary certificate to Beijing Applied Biological Technologies (XABT) for the donation of 2019-nCoV Nucleic Acid Detection Kits to support Vientiane's efforts at epidemic prevention and control in 2021. At the same time, the deputy director of the Vientiane's foreign affairs office, sent a letter of thanks to XABT on behalf of the Vientiane Municipal Government and Epidemic Prevention and Control Committee.During the last coronavirus outbreak in Laos in April this year, XABT donated 5,040 Multiple Real Time PCR Kits for Detection of 2019-nCoV and provided full technical service support to Vientiane to help the city control the spread of the disease through in-depth international cooperation.Virus knows no borders, but the worst of times reveals the best in people. Since the outbreak of COVID-19, XABT has undertaken corporate social responsibility with practical actions and donated nucleic acid detection and extraction kits to Italy, Iran, Malaysia, Thailand, Peru and Bangladesh to support their fights against the epidemic. The company will continue to make positive contributions to continue the effort at controlling the epidemic worldwide. Nucleic acid detection is an important testing and screening method for 2019-nCoV used by the World Health Organization (WHO) and national health authorities. XABT, among all the companies that have obtained the registration certificate from the National Medical Products Administration of China for the coronavirus nucleic acid detection reagent, is one of the few high-tech companies producing the rapid detection technology covering three genes, ORF1ab, N and E. The company's 2019-nCoV nucleic acid detection kit (fluorescence PCR method) can achieve up to 99.9% accuracy due to the specific binding at the molecular level and was included in the WHO Emergency Use Listing in May 2020. The company has received the ISO13485 system certification, and its products, all of which conform to the EU's CE certification standards, are being adopted by more and more countries as a tool to control and prevent the further spread of the virus as well as being recognized as the most effective solution by more and more organizations.For more information:Company website: LinkedIn, Facebook, YouTubePhoto - - Advertisements

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing xABT

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

xABT is included in 5 Expert Collections, including Medical Devices.


Medical Devices

7,476 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health & Wellness Assessment

2,350 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Infectious Disease

2,215 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.



823 items

Companies involved in the capture, sequencing, and/or analysis of genetic data



1,025 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

xABT Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

xABT Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.